Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-214 mimic
- Development stage
- Preclinical
- Lead developer
- Baker Heart and Diabetes Institute
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
miR-214 mimic is a synthetic double-stranded RNA oligonucleotide designed to mimic the activity of endogenous microRNA-214 (miR-214). It functions by binding to the 3'-untranslated region (3'-UTR) of target mRNAs, leading to translational repression or mRNA degradation. Key direct targets of miR-214 include protein diaphanous homolog 1 (DIAPH1), phosphatase and tensin homolog (PTEN), Toll-like receptor 4 (TLR4), and prostaglandin G/H synthase 2 (PTGS2/COX-2). In preclinical models of diabetic kidney disease (DKD), miR-214 mimic therapy has been shown to exert antifibrotic and anti-inflammatory effects, activate lipid and mitochondrial metabolic pathways, and suppress inflammatory and fibrotic transcriptional programs. It is also widely used as a research tool to investigate the role of miR-214 in various cancers, cardiovascular diseases, and renal disorders.
- Other names
- hsa-miR-214 mimichsa-miR214 mimichsa-miR 214 mimicmicroRNA-214 mimicmicroRNA214 mimicmicroRNA 214 mimicmiR-214-3p mimicmiR214-3p mimicmiR 214-3p mimic
02
Targets
E3 ligase (E3 ubiquitin ligases)FOXM1 (Forkhead box protein M1)TFAM (Mitochondrial transcription factor A)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)DIAPH1 (Mammalian diaphanous-related formin 1)PTK6 (Protein-tyrosine kinase 6)PIM1 (Proviral integration site for moloney murine leukemia virus kinase 1)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on miR-214 mimic.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-214 mimic.